8-KAMRJanuary2015   

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

WASHINGTON, D.C. 20549

_______________________

FORM 8-K

CURRENT REPORT 

PURSUANT TO SECTION 13 OR 15(D) OF 

THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): January 7, 2015

ALEXION PHARMACEUTICALS, INC.

-----------------------------------------------------------

(Exact name of registrant as specified in its charter)

[DATA_TABLE_REMOVED]

352 Knotter Drive, Cheshire, Connecticut 06410

---------------------------------------------------------------

(Address of Principal Executive Offices) (Zip Code)

Registrantâ€™s telephone number, including area code: (203) 272-2596

[DATA_TABLE_REMOVED]

Item 8.01 Other Events. 

On January 7, 2015, Alexion Pharmaceuticals, Inc. issued a press release announcing results from its randomized, open-label, multicenter Phase 2 clinical trial to determine the safety and efficacy of eculizumab in the prevention of antibody mediated rejection in living-donor kidney transplant recipients requiring desensitization.

A copy of the press release is attached to this report as Exhibit 99.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits. 

(d) Exhibits 

99.1 Press Release issued by Alexion Pharmaceuticals, Inc. on January 7, 2015.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

[DATA_TABLE_REMOVED]